Chemotherapy-Induced Myelosuppression Treatment Market Size, Share, Trends, Growth 2032

Chemotherapy-Induced Myelosuppression Treatment Market

Chemotherapy-Induced Myelosuppression Treatment Market By Indication (Anaemia, Neutropenia and Thrombocytopenia), By Drug Class (Thrombopoietic Agents, Erythropoietin Stimulating Agents, Iron Supplements, Growth Factors and Others), By Route of Administration (Injectable and Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies), And By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2024 – 2032

Category: Biotechnology Report Format : PDF Pages: 126 Report Code: ZMR-5000 Published Date: Apr-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 Growth Rate (in %) Base Year
USD 8.06 billion USD 10.99 billion CAGR at 3.50%. 2023

Chemotherapy-Induced Myelosuppression T Market

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Chemotherapy-Induced Myelosuppression Treatment Market, 2016 - 2025, (USD Million)
    • 2.2. Chemotherapy-Induced Myelosuppression Treatment Market: Snapshot
  • Chapter 3. Global Chemotherapy-Induced Myelosuppression Treatment Market – Industry Analysis
    • 3.1. Chemotherapy-Induced Myelosuppression Treatment Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Availability of advanced treatment options like chemotherapy, surgeries, radiotherapy
      • 3.2.2. Increasing preference for chemotherapy for cancer treatment
      • 3.2.3. Promising drug pipelines
      • 3.2.4. Increasing prevalence of cancer
    • 3.3. Restraints
      • 3.3.1. Loss of patent exclusivity
      • 3.3.2. Intense competition
    • 3.4. Opportunity
      • 3.4.1. Emerging Markets
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by indication segment
      • 3.6.2. Market attractiveness analysis by drug class segment
      • 3.6.3. Market attractiveness analysis by route of administration segment
      • 3.6.4. Market attractiveness analysis by distribution channel segment
      • 3.6.5. Market attractiveness analysis by regional segment
  • Chapter 4. Global Chemotherapy-Induced Myelosuppression Treatment Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global chemotherapy-induced myelosuppression treatment market: company market share analysis, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New indication launches
      • 4.2.3. Agreements, partnerships, cullaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Chemotherapy-Induced Myelosuppression Treatment Market – Indication Segment Analysis
    • 5.1. Global chemotherapy-induced myelosuppression treatment market overview: by indication
      • 5.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by indication, 2018 and 2025
    • 5.2. Neutropenia
      • 5.2.1. Global chemotherapy-induced myelosuppression treatment market by Neutropenia, 2016-2025 (USD Million)
    • 5.3. Anaemia
      • 5.3.1. Global chemotherapy-induced myelosuppression treatment market by Anaemia, 2016-2025 (USD Million)
    • 5.4. Thrombocytopenia
      • 5.4.1. Global chemotherapy-induced myelosuppression treatment market by Thrombocytopenia, 2016-2025 (USD Million)
  • Chapter 6. Global Chemotherapy-Induced Myelosuppression Treatment Market – Drug Class Segment Analysis
    • 6.1. Global chemotherapy-induced myelosuppression treatment market overview: by drug class
      • 6.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by drug class, 2018 and 2025
    • 6.2. Growth Factors
      • 6.2.1. Global chemotherapy-induced myelosuppression treatment market by Growth Factors, 2016-2025 (USD Million)
    • 6.3. Erythropoietin Stimulating Agents
      • 6.3.1. Global chemotherapy-induced myelosuppression treatment market by Erythropoietin Stimulating Agents, 2016-2025 (USD Million)
    • 6.4. Thrombopoietic Agents
      • 6.4.1. Global chemotherapy-induced myelosuppression treatment market by Thrombopoietic Agents, 2016-2025 (USD Million)
    • 6.5. Iron Supplements
      • 6.5.1. Global chemotherapy-induced myelosuppression treatment market by Iron Supplements, 2016-2025 (USD Million)
    • 6.6. Others
      • 6.6.1. Global chemotherapy-induced myelosuppression treatment market by Others, 2016-2025 (USD Million)
  • Chapter 7. Global Chemotherapy-Induced Myelosuppression Treatment Market – Route of Administration Segment Analysis
    • 7.1. Global chemotherapy-induced myelosuppression treatment market overview: by route of administration
      • 7.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by route of administration, 2018 and 2025
    • 7.2. Oral
      • 7.2.1. Global chemotherapy-induced myelosuppression treatment market by Oral, 2016-2025 (USD Million)
    • 7.3. Injectable
      • 7.3.1. Global chemotherapy-induced myelosuppression treatment market by Injectable, 2016-2025 (USD Million)
  • Chapter 8. Global Chemotherapy-Induced Myelosuppression Treatment Market – Distribution Channel Segment Analysis
    • 8.1. Global chemotherapy-induced myelosuppression treatment market overview: by distribution channel
      • 8.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by distribution channel, 2018 and 2025
    • 8.2. Hospital Pharmacies
      • 8.2.1. Global chemotherapy-induced myelosuppression treatment market by Hospital Pharmacies, 2016-2025 (USD Million)
    • 8.3. Retail Pharmacies
      • 8.3.1. Global chemotherapy-induced myelosuppression treatment market by Retail Pharmacies, 2016-2025 (USD Million)
    • 8.4. Online Pharmacies
      • 8.4.1. Global chemotherapy-induced myelosuppression treatment market by Online Pharmacies, 2016-2025 (USD Million)
  • Chapter 9. Global Chemotherapy-Induced Myelosuppression Treatment Market - Regional Analysis
    • 9.1. Global chemotherapy-induced myelosuppression treatment market overview: by region
      • 9.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by region, 2018 and 2025
    • 9.2. North America
      • 9.2.1. North America chemotherapy-induced myelosuppression treatment market, by country, 2016-2025 (USD Million)
      • 9.2.2. North America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.2.3. North America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.2.4. North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.2.5. North America chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.2.6. The U.S.
        • 9.2.6.1. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.2.6.2. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.2.6.3. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.2.6.4. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.2.7. Rest of North America
        • 9.2.7.1. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.2.7.2. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.2.7.3. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.2.7.4. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 9.3. Europe
      • 9.3.1. Europe chemotherapy-induced myelosuppression treatment market, by country, 2016-2025 (USD Million)
      • 9.3.2. Europe chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.3.3. Europe chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.3.4. Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.3.5. Europe chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.3.6. U.K.
        • 9.3.6.1. U.K. chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.3.6.2. U.K. chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.3.6.3. U.K. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.3.6.4. U.K. chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.3.7. France
        • 9.3.7.1. France chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.3.7.2. France chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.3.7.3. France chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.3.7.4. France chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.3.8. Germany
        • 9.3.8.1. Germany chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.3.8.2. Germany chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.3.8.3. Germany chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.3.8.4. Germany chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.3.9. Rest of Europe
        • 9.3.9.1. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.3.9.2. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.3.9.3. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.3.9.4. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific chemotherapy-induced myelosuppression treatment market, by country, 2016-2025 (USD Million)
      • 9.4.2. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.4.3. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.4.4. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.4.5. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.4.6. China
        • 9.4.6.1. China chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.4.6.2. China chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.4.6.3. China chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.4.6.4. China chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.4.7. Japan
        • 9.4.7.1. Japan chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.4.7.2. Japan chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.4.7.3. Japan chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.4.7.4. Japan chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.4.8. India
        • 9.4.8.1. India chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.4.8.2. India chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.4.8.3. India chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.4.8.4. India chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.4.9. Rest of Asia Pacific
        • 9.4.9.1. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.4.9.2. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.4.9.3. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.4.9.4. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America chemotherapy-induced myelosuppression treatment market, by country, 2016-2025 (USD Million)
      • 9.5.2. Latin America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.5.3. Latin America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.5.4. Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.5.5. Latin America chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.5.6.2. Brazil chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.5.6.3. Brazil chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.5.6.4. Brazil chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.5.7. Rest of Latin America
        • 9.5.7.1. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.5.7.2. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.5.7.3. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.5.7.4. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 9.6. Middle East & Africa
      • 9.6.1. Middle East & Africa chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
      • 9.6.2. Middle East & Africa chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.6.3. Middle East & Africa chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.6.4. Middle East & Africa chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.6.5. Middle East & Africa chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
  • Chapter 10. Company Profiles
    • 10.1. Teva Pharmaceutical Industries Ltd.
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product Portfolio
      • 10.1.4. Business Strategy
      • 10.1.5. Recent Developments
    • 10.2. Amgen Inc.
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Product Portfolio
      • 10.2.4. Business Strategy
      • 10.2.5. Recent Developments
    • 10.3. Janssen Global Services, LLC
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Product Portfolio
      • 10.3.4. Business Strategy
      • 10.3.5. Recent Developments
    • 10.4. Pfizer Inc.
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Product Portfolio
      • 10.4.4. Business Strategy
      • 10.4.5. Recent Developments
    • 10.5. Mylan NV
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Product Portfolio
      • 10.5.4. Business Strategy
      • 10.5.5. Recent Developments
    • 10.6. Mission Pharmacal Company
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Product Portfolio
      • 10.6.4. Business Strategy
      • 10.6.5. Recent Developments
    • 10.7. Myelo Therapeutics GmbH
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Product Portfolio
      • 10.7.4. Business Strategy
      • 10.7.5. Recent Developments
    • 10.8. Dova Pharmaceuticals
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Product Portfolio
      • 10.8.4. Business Strategy
      • 10.8.5. Recent Developments
    • 10.9. Partner Therapeutics, Inc.
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Product Portfolio
      • 10.9.4. Business Strategy
      • 10.9.5. Recent Developments
    • 10.10. Novartis AG
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Product Portfolio
      • 10.10.4. Business Strategy
      • 10.10.5. Recent Developments

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
4. Porter’s five forces analysis: chemotherapy-induced myelosuppression treatment market
5. Global chemotherapy-induced myelosuppression treatment market attractiveness, by indication
6. Global chemotherapy-induced myelosuppression treatment market attractiveness, by drug class
7. Global chemotherapy-induced myelosuppression treatment market attractiveness, by route of administration
8. Global chemotherapy-induced myelosuppression treatment market attractiveness, by distribution channel
9. Global chemotherapy-induced myelosuppression treatment market revenue share, by indication, 2018 and 2025
10. Global chemotherapy-induced myelosuppression treatment market by Neutropenia, 2016-2025 (USD Million)
11. Global chemotherapy-induced myelosuppression treatment market by Anaemia, 2016-2025 (USD Million)
12. Global chemotherapy-induced myelosuppression treatment market by Thrombocytopenia, 2016-2025 (USD Million)
13. Global chemotherapy-induced myelosuppression treatment market revenue share, by drug class, 2018 and 2025
14. Global chemotherapy-induced myelosuppression treatment market by Growth Factors, 2016-2025 (USD Million)
15. Global chemotherapy-induced myelosuppression treatment market by Erythropoietin Stimulating Agents, 2016-2025 (USD Million)
16. Global chemotherapy-induced myelosuppression treatment market by Thrombopoietic Agents, 2016-2025 (USD Million)
17. Global chemotherapy-induced myelosuppression treatment market by Iron Supplements, 2016-2025 (USD Million)
18. Global chemotherapy-induced myelosuppression treatment market by Others, 2016-2025 (USD Million)
19. Global chemotherapy-induced myelosuppression treatment market revenue share, by route of administration, 2018 and 2025
20. Global chemotherapy-induced myelosuppression treatment market by Oral, 2016-2025 (USD Million)
21. Global chemotherapy-induced myelosuppression treatment market by Injectable, 2016-2025 (USD Million)
22. Global chemotherapy-induced myelosuppression treatment market revenue share, by distribution channel, 2018 and 2025
23. Global chemotherapy-induced myelosuppression treatment market by Hospital Pharmacies, 2016-2025 (USD Million)
24. Global chemotherapy-induced myelosuppression treatment market by Retail Pharmacies, 2016-2025 (USD Million)
25. Global chemotherapy-induced myelosuppression treatment market by Online Pharmacies, 2016-2025 (USD Million)
26. Global chemotherapy-induced myelosuppression treatment market revenue share, by region, 2018 & 2025
27. North America chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
28. Europe chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
29. Asia Pacific chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
30. Latin America chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
31. Middle East & Africa chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
 
 


Table Of Tables

List of Tables

1. Global chemotherapy-induced myelosuppression treatment market: snapshot
2. Drivers for chemotherapy-induced myelosuppression treatment market: impact analysis
3. Restraints for chemotherapy-induced myelosuppression treatment market: impact analysis
4. North America chemotherapy-induced myelosuppression treatment market revenue, by country, 2016-2025 (USD Million)
5. North America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
6. North America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
7. North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
8. North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
9. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
10. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
11. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
12. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
13. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
14. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
15. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
16. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
17. Europe chemotherapy-induced myelosuppression treatment market revenue, by country, 2016-2025 (USD Million)
18. Europe chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
19. Europe chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
20. Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
21. Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
22. U.K. chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
23. U.K. chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
24. U.K. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
25. U.K. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
26. France chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
27. France chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
28. France chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
29. France chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
30. Germany chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
31. Germany chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
32. Germany chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
33. Germany chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
34. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
35. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
36. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
37. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
38. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by country, 2016-2025 (USD Million)
39. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
40. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
41. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
42. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
43. China chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
44. China chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
45. China chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
46. China chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
47. Japan chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
48. Japan chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
49. Japan chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
50. Japan chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
51. India chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
52. India chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
53. India chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
54. India chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
55. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
56. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
57. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
58. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
59. Latin America chemotherapy-induced myelosuppression treatment market revenue, by country, 2016-2025 (USD Million)
60. Latin America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
61. Latin America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
62. Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
63. Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
64. Brazil chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
65. Brazil chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
66. Brazil chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
67. Brazil chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
68. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
69. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
70. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
71. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
72. Middle  East & Africa chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
73. Middle  East & Africa chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
74. Middle  East & Africa chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
75. Middle  East & Africa chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
 

Methodology

FrequentlyAsked Questions

The management and prevention of a condition in which the toxic effects of chemotherapy drugs impair the bone marrow's capacity to produce blood cells is referred to as chemotherapy-induced myelosuppression treatment. A prevalent and potentially severe adverse effect of chemotherapy is myelosuppression, which can result in reduced production of platelets (thrombocytopenia), red blood cells (neutropenia), and white blood cells (neutropenia). Chemotherapy-undergoing cancer patients may be more susceptible to infections, fatigue, and hemorrhage complications due to this condition.

The escalating prevalence of cancer on an international scale augments the need for myelosuppression therapy induced by chemotherapy. As the number of patients undergoing chemotherapy to treat cancer increases, so does the need for efficient management of complications associated with myelosuppression.

The global chemotherapy-induced myelosuppression treatment market size was worth around USD 8.06 billion in 2023 and is predicted to grow to around USD 10.99 billion by 2032.

The global chemotherapy-induced myelosuppression treatment market with a compound annual growth rate (CAGR) of roughly 3.50% between 2024 and 2032.

Economic development, increasing geriatric population base and cancer prevalence, healthcare infrastructure improvement, increasing healthcare spending and disposable income, and growing awareness are important factors attributing to the rapid growth in this region. On the other hand Latin America will experience moderate growth in the coming years. Middle East and Africa will register slower growth in the years to come.

Teva Pharmaceutical Industries Ltd., Amgen Inc., Janssen Global Services, LLC, Pfizer Inc., Mylan NV, Mission Pharmacal Company, Myelo Therapeutics GmbH, Dova Pharmaceuticals, Partner Therapeutics, Inc. and Novartis AG

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed